Abstract
An improved understanding of human T-cell-mediated immunity in COVID-19 is important if we are to optimize therapeutic and vaccine strategies. Experience with influenza shows that infection primes CD8+ T-cell memory to shared peptides presented by common HLA types like HLA-A2. Following re-infection, cross-reactive CD8+ T-cells enhance recovery and diminish clinical severity. Stimulating peripheral blood mononuclear cells from COVID-19 convalescent patients with overlapping peptides from SARS-CoV-2 Spike, Nucleocapsid and Membrane proteins led to the clonal expansion of SARS-CoV-2-specific CD8+ and CD4+ T-cells in vitro, with CD4+ sets being typically robust. For CD8+ T-cells taken directly ex vivo, we identified two HLA-A*02:01-restricted SARS-CoV-2 epitopes, A2/S269–277 and A2/Orf1ab3183–3191. Using peptide-HLA tetramer enrichment, direct ex vivo assessment of the A2/S269+CD8+ and A2/Orf1ab3183+CD8+ populations indicated that the more prominent A2/S269+CD8+ set was detected at comparable frequency (∼1.3×10−5) in acute and convalescent HLA-A*02:01+ patients. But, while the numbers were higher than those found in uninfected HLA-A*02:01+ donors (∼2.5×10−6), they were low when compared with frequencies for influenza-specific (A2/M158) and EBV-specific (A2/BMLF1280) (∼1.38×10−4) populations. Phenotypic analysis ex vivo of A2/S269+CD8+ T-cells from COVID-19 convalescents showed that A2/S269+CD8+ T-cells were predominantly negative for the CD38, HLA-DR, PD-1 and CD71 activation markers, although the majority of total CD8+ T-cells were granzyme and/or perforin-positive. Furthermore, the bias towards naïve, stem cell memory and central memory A2/S269+CD8+ T-cells rather than effector memory populations suggests that SARS-CoV2 infection may be compromising CD8+ T-cell activation. Priming with an appropriate vaccine may thus have great value for optimizing protective CD8+ T-cell immunity in COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Clifford Craig Foundation to KLF and KK, NHMRC Leadership Investigator Grant to KK (1173871), NHMRC Program Grant to DLD (1132975), Research Grants Council of the Hong Kong Special Administrative Region, China (T11-712/19-N) to KK, the Victorian Government (SJK, AKW), MRFF award (2002073) to SJK and AKW, MRFF Award (1202445) to KK, NHMRC program grant 1149990 (SJK), NHMRC project grant 1162760 (AKW). AWC is supported by a NHMRC Career Development Fellowship (1140509), KK by NHMRC Senior Research Fellowship (1102792), DLD by a NHMRC Principal Research Fellowship (1137285) and SJK by NHMRC Senior Principal Research Fellowship (1136322). JR is supported by an ARC Laureate fellowship. JRH is supported by the Melbourne Research Scholarship from The University of Melbourne. CES has received funding from the European Union Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement (792532). LH is supported by the Melbourne International Research Scholarship (MIRS) and the Melbourne International Fee Remission Scholarship (MIFRS) from The University of Melbourne. JAJ is supported by an NHMRC Early Career Fellowship (ECF) (1123673).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Experiments conformed to the Declaration of Helsinki Principles and the Australian National Health and Medical Research Council Code of Practice. Written informed consents were obtained from all blood donors prior to the study. Lung tissues were obtained from deceased organ donors after written informed consents from the next of kin. Written informed consents were obtained from participants parents or guardians for underage tonsil tissue donors. The study was approved by the Alfred Hospital (280/14), The University of Melbourne (2056689, 2056761, 1442952, 1955465, and 1443389), the Australian Red Cross Lifeblood (ID 2015/8), the Tasmanian Health and Medical (ID H0017479) and the James Cook University (H7886) Human Research Ethics Committees.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data are available upon request
